Literature DB >> 30354612

Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?

Axel Sarrias1,2, Antoni Bayes-Genis1,2.   

Abstract

Entities:  

Keywords:  arrhythmias, cardiac; death, sudden; heart failure

Mesh：

Substances：

Year:  2018        PMID： 30354612     DOI： 10.1161/CIRCULATIONAHA.118.034755

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  15 in total

1.  Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation.

Authors:  Lourdes Vicent; Francisco Méndez-Zurita; Xavier Viñolas; Concepción Alonso-Martín; Carles Moliner Arbòs; Julia Pamies; R Oscar Alcalde; Miriam Juárez; Vanesa Bruña; Carolina Devesa; Iago Sousa-Casasnovas; Francisco Fernández-Avilés; Manuel Martínez-Sellés
Journal:  Heart Vessels       Date:  2019-06-22       Impact factor: 2.037

2.  Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway.

Authors:  Ferhat Dindaş; Hüseyin Güngör; Mehmet Ekici; Pınar Akokay; Füsun Erhan; Mustafa Doğduş; Mehmet Birhan Yılmaz
Journal:  Anatol J Cardiol       Date:  2021-11       Impact factor: 1.596

Review 3.  Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Juan Gao; Cong Zhao; Wen-Zhong Zhang; Song Liu; Hui Xin; Zhe-Xun Lian
Journal:  Heart Fail Rev       Date:  2022-10-03       Impact factor: 4.654

Review 4.  A narrative review on sacubitril/valsartan and ventricular arrhythmias.

Authors:  Zhaoyang Wei; Meiwei Zhang; Qian Zhang; Linan Gong; Xiangyu Wang; Zanzan Wang; Ming Gao; Zhiguo Zhang
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

5.  Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure.

Authors:  Jörg Eiringhaus; Christoph M Wünsche; Petros Tirilomis; Jonas Herting; Nadja Bork; Viacheslav O Nikolaev; Gerd Hasenfuss; Samuel Sossalla; Thomas H Fischer
Journal:  ESC Heart Fail       Date:  2020-07-25

Review 6.  Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices.

Authors:  Sijing Cheng; Nixiao Zhang; Wei Hua
Journal:  Am J Cardiovasc Drugs       Date:  2020-10-28       Impact factor: 3.571

Review 7.  Sympathetic Activation and Arrhythmogenesis after Myocardial Infarction: Where Do We Stand?

Authors:  Konstantinos C Zekios; Eleni-Taxiarchia Mouchtouri; Panagiotis Lekkas; Dimitrios N Nikas; Theofilos M Kolettis
Journal:  J Cardiovasc Dev Dis       Date:  2021-05-15

8.  The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator.

Authors:  Vincenzo Russo; Roberta Bottino; Anna Rago; Andrea Antonio Papa; Biagio Liccardo; Riccardo Proietti; Vincenzo Manna; Paolo Golino; Antonio D'Onofrio; Gerardo Nigro
Journal:  J Clin Med       Date:  2020-04-13       Impact factor: 4.241

Review 9.  Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence.

Authors:  Hong-Mi Choi; Mi-Seung Shin
Journal:  Korean J Intern Med       Date:  2020-04-29       Impact factor: 2.884

Review 10.  Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.

Authors:  Marcin Książczyk; Małgorzata Lelonek
Journal:  Heart Fail Rev       Date:  2020-05       Impact factor: 4.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.